PolarityTE Inc (Nasdaq: PTE), a US-based commercial stage biotechnology company focused on discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced yesterday that it has named Matt Kemp as its new chief commercial officer.

The company says that Kemp will be integral in leading efforts as its human cellular and tissue-based product, SkinTE, moves toward a full national launch and in bringing other PolarityTE pipeline technologies and core 'TE' products to market globally.

With around 20 years of leadership experience, Kemp has an extensive record of driving profitable growth in both large and small biotech, medical device and pharmaceutical companies. He most recently served as chief commercial officer at Dendreon Pharmaceuticals, a biotechnology company whose first product is an autologous immunotherapy for the treatment of advanced prostate cancer made from a patient's own immune cells. While at Dendreon, it is claimed that he helped champion a complete turnaround and the execution of a successful commercial strategy with the novel autologous cellular immunotherapy. Dendreon went from a net negative business to returning three consecutive years of USD100+ million in profit during his tenure with the company. He has also held commercial leadership positions at Zimmer Biomet, Allergan and AbbVie across a variety of technologies, products and markets.

Prior to joining PolarityTE, Kemp served as chief commercial officer at Dendreon Pharmaceuticals LLC, a pioneer in personalised medicine. Prior to Dendreon, he held commercial leadership positions at Zimmer Biomet, Allergan and AbbVie. He also served six years in the Air Force, rising to the rank of captain.